Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosifloxuridine nafalbenamide (Primary) ; Antineoplastics; Docetaxel; Folinic acid; Pembrolizumab; Programmed cell death 1 receptor antagonists
  • Indications Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NuTide:303
  • Sponsors NuCana

    • Most Recent Events

    • 28 Feb 2025 Planned End Date changed from 1 Jan 2025 to 1 Dec 2025.
    • 28 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Dec 2025.
    • 11 Nov 2024 According to a NuCana media release, following treatment of the first 4 patients in module 2, enrollment was put on hold due to toxicity challenges with docetaxel.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top